http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 07 Apr 2025 16:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Cyclo+Therapeutics%2C+Inc.+++++++++++++/24609174.html si-local-file:///var/storage/secattach/20250407/24609174.html http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Cyclo+Therapeutics%2C+Inc.+++++++++++++/24609174.html Mon, 07 Apr 2025 16:05:00 -0400 CYTH O.47731837 http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Cyclo+Therapeutics%2C+Inc.+++++++++++++/24609174.html si-local-file:///var/storage/secattach/20250407/24609174.html http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Cyclo+Therapeutics%2C+Inc.+++++++++++++/24609174.html Mon, 07 Apr 2025 16:05:00 -0400 CYTH O.47731837 http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++Cyclo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/24550625.html si-local-file:///var/storage/secattach/20250326/24550625.html http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++Cyclo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/24550625.html Wed, 26 Mar 2025 11:26:00 -0400 CYTH O.47731837 http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++Cyclo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/24550625.html si-local-file:///var/storage/secattach/20250326/24550625.html http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++Cyclo+Therapeutics%2C+Inc.+++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/24550625.html Wed, 26 Mar 2025 11:26:00 -0400 CYTH O.47731837 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cyclo+Therapeutics%2C+Inc.++For%3A+Mar+25/24548859.html si-local-file:///var/storage/secattach/20250326/24548859.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cyclo+Therapeutics%2C+Inc.++For%3A+Mar+25/24548859.html Wed, 26 Mar 2025 07:06:00 -0400 CYTH O.47731837 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cyclo+Therapeutics%2C+Inc.++For%3A+Mar+25/24548859.html si-local-file:///var/storage/secattach/20250326/24548859.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cyclo+Therapeutics%2C+Inc.++For%3A+Mar+25/24548859.html Wed, 26 Mar 2025 07:06:00 -0400 CYTH O.47731837 http://www.streetinsider.com/Corporate+News/Rafael+Holdings+%28RFL%29+Completes+Merger+with+Cyclo+Therapeutics+%28CYTH%29+Following+Shareholder+Approvals/24548650.html <p>Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (NASDAQ: CYTH) today announced the closing of their business combination following approval by shareholders of both companies. Rafael Holdings issued shares of its Class B common stock to Cyclo Therapeutics’ shareholders representing approximately 22% of the combined company, based on the exchange ratio in the merger agreement between the parties determined to be 0.3525. Rafael also issued warrants to purchase shares of Rafael Class B common stock to certain holders of Cyclo warrants. Rafael Holdings has identified Trappsol^® Cyclo™ as its lead clinical asset and looks forward to the TransportNPC™ 48-week http://www.streetinsider.com/Corporate+News/Rafael+Holdings+%28RFL%29+Completes+Merger+with+Cyclo+Therapeutics+%28CYTH%29+Following+Shareholder+Approvals/24548650.html Wed, 26 Mar 2025 06:50:46 -0400 CYTH RFL http://www.streetinsider.com/Corporate+News/Rafael+Holdings+%28RFL%29+Completes+Merger+with+Cyclo+Therapeutics+%28CYTH%29+Following+Shareholder+Approvals/24548650.html <p>Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (NASDAQ: CYTH) today announced the closing of their business combination following approval by shareholders of both companies. Rafael Holdings issued shares of its Class B common stock to Cyclo Therapeutics’ shareholders representing approximately 22% of the combined company, based on the exchange ratio in the merger agreement between the parties determined to be 0.3525. Rafael also issued warrants to purchase shares of Rafael Class B common stock to certain holders of Cyclo warrants. Rafael Holdings has identified Trappsol^® Cyclo™ as its lead clinical asset and looks forward to the TransportNPC™ 48-week http://www.streetinsider.com/Corporate+News/Rafael+Holdings+%28RFL%29+Completes+Merger+with+Cyclo+Therapeutics+%28CYTH%29+Following+Shareholder+Approvals/24548650.html Wed, 26 Mar 2025 06:50:46 -0400 CYTH RFL http://www.streetinsider.com/Mergers+and+Acquisitions/Rafael+Holdings+%28RFL%29+Completes+Merger+with+Cyclo+Therapeutics+%28CYTH%29+Following+Shareholder+Approvals/24548650.html <p>Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (NASDAQ: CYTH) today announced the closing of their business combination following approval by shareholders of both companies. Rafael Holdings issued shares of its Class B common stock to Cyclo Therapeutics’ shareholders representing approximately 22% of the combined company, based on the exchange ratio in the merger agreement between the parties determined to be 0.3525. Rafael also issued warrants to purchase shares of Rafael Class B common stock to certain holders of Cyclo warrants. Rafael Holdings has identified Trappsol^® Cyclo™ as its lead clinical asset and looks forward to the TransportNPC™ 48-week http://www.streetinsider.com/Mergers+and+Acquisitions/Rafael+Holdings+%28RFL%29+Completes+Merger+with+Cyclo+Therapeutics+%28CYTH%29+Following+Shareholder+Approvals/24548650.html Wed, 26 Mar 2025 06:50:46 -0400 CYTH RFL http://www.streetinsider.com/Mergers+and+Acquisitions/Rafael+Holdings+%28RFL%29+Completes+Merger+with+Cyclo+Therapeutics+%28CYTH%29+Following+Shareholder+Approvals/24548650.html <p>Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (NASDAQ: CYTH) today announced the closing of their business combination following approval by shareholders of both companies. Rafael Holdings issued shares of its Class B common stock to Cyclo Therapeutics’ shareholders representing approximately 22% of the combined company, based on the exchange ratio in the merger agreement between the parties determined to be 0.3525. Rafael also issued warrants to purchase shares of Rafael Class B common stock to certain holders of Cyclo warrants. Rafael Holdings has identified Trappsol^® Cyclo™ as its lead clinical asset and looks forward to the TransportNPC™ 48-week http://www.streetinsider.com/Mergers+and+Acquisitions/Rafael+Holdings+%28RFL%29+Completes+Merger+with+Cyclo+Therapeutics+%28CYTH%29+Following+Shareholder+Approvals/24548650.html Wed, 26 Mar 2025 06:50:46 -0400 CYTH RFL http://www.streetinsider.com/Press+Releases/Rafael+Holdings+Completes+Merger+with+Cyclo+Therapeutics+Following+Shareholder+Approvals/24548647.html <p><strong>Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025</strong></p><p align="left">NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (NASDAQ: CYTH) today announced the closing of their business combination following approval by shareholders of both companies. Rafael Holdings issued shares of its Class B common stock to Cyclo Therapeutics’ shareholders representing approximately 22% of the combined http://www.streetinsider.com/Press+Releases/Rafael+Holdings+Completes+Merger+with+Cyclo+Therapeutics+Following+Shareholder+Approvals/24548647.html Wed, 26 Mar 2025 06:50:00 -0400 CYTH RFL RFL http://www.streetinsider.com/Press+Releases/Rafael+Holdings+Completes+Merger+with+Cyclo+Therapeutics+Following+Shareholder+Approvals/24548647.html <p><strong>Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025</strong></p><p align="left">NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (NASDAQ: CYTH) today announced the closing of their business combination following approval by shareholders of both companies. Rafael Holdings issued shares of its Class B common stock to Cyclo Therapeutics’ shareholders representing approximately 22% of the combined http://www.streetinsider.com/Press+Releases/Rafael+Holdings+Completes+Merger+with+Cyclo+Therapeutics+Following+Shareholder+Approvals/24548647.html Wed, 26 Mar 2025 06:50:00 -0400 CYTH RFL RFL http://www.streetinsider.com/Press+Releases/Rafael+Holdings+Completes+Merger+with+Cyclo+Therapeutics+Following+Shareholder+Approvals/24548647.html <p><strong>Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025</strong></p><p align="left">NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (NASDAQ: CYTH) today announced the closing of their business combination following approval by shareholders of both companies. Rafael Holdings issued shares of its Class B common stock to Cyclo Therapeutics’ shareholders representing approximately 22% of the combined http://www.streetinsider.com/Press+Releases/Rafael+Holdings+Completes+Merger+with+Cyclo+Therapeutics+Following+Shareholder+Approvals/24548647.html Wed, 26 Mar 2025 06:50:00 -0400 CYTH RFL RFL http://www.streetinsider.com/Globe+Newswire/Rafael+Holdings+Completes+Merger+with+Cyclo+Therapeutics+Following+Shareholder+Approvals/24548647.html <p><strong>Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025</strong></p><p align="left">NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (NASDAQ: CYTH) today announced the closing of their business combination following approval by shareholders of both companies. Rafael Holdings issued shares of its Class B common stock to Cyclo Therapeutics’ shareholders representing approximately 22% of the combined http://www.streetinsider.com/Globe+Newswire/Rafael+Holdings+Completes+Merger+with+Cyclo+Therapeutics+Following+Shareholder+Approvals/24548647.html Wed, 26 Mar 2025 06:50:00 -0400 CYTH RFL RFL http://www.streetinsider.com/Globe+Newswire/Rafael+Holdings+Completes+Merger+with+Cyclo+Therapeutics+Following+Shareholder+Approvals/24548647.html <p><strong>Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025</strong></p><p align="left">NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (NASDAQ: CYTH) today announced the closing of their business combination following approval by shareholders of both companies. Rafael Holdings issued shares of its Class B common stock to Cyclo Therapeutics’ shareholders representing approximately 22% of the combined http://www.streetinsider.com/Globe+Newswire/Rafael+Holdings+Completes+Merger+with+Cyclo+Therapeutics+Following+Shareholder+Approvals/24548647.html Wed, 26 Mar 2025 06:50:00 -0400 CYTH RFL RFL http://www.streetinsider.com/Globe+Newswire/Rafael+Holdings+Completes+Merger+with+Cyclo+Therapeutics+Following+Shareholder+Approvals/24548647.html <p><strong>Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025</strong></p><p align="left">NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (NASDAQ: CYTH) today announced the closing of their business combination following approval by shareholders of both companies. Rafael Holdings issued shares of its Class B common stock to Cyclo Therapeutics’ shareholders representing approximately 22% of the combined http://www.streetinsider.com/Globe+Newswire/Rafael+Holdings+Completes+Merger+with+Cyclo+Therapeutics+Following+Shareholder+Approvals/24548647.html Wed, 26 Mar 2025 06:50:00 -0400 CYTH RFL RFL http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cyclo+Therapeutics%2C+Inc.++For%3A+Mar+20/24540145.html si-local-file:///var/storage/secattach/20250324/24540145.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cyclo+Therapeutics%2C+Inc.++For%3A+Mar+20/24540145.html Mon, 24 Mar 2025 16:30:00 -0400 CYTH O.47731837 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cyclo+Therapeutics%2C+Inc.++For%3A+Mar+20/24540145.html si-local-file:///var/storage/secattach/20250324/24540145.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cyclo+Therapeutics%2C+Inc.++For%3A+Mar+20/24540145.html Mon, 24 Mar 2025 16:30:00 -0400 CYTH O.47731837 http://www.streetinsider.com/Press+Releases/Rafael+Holdings+Reports+Second+Quarter+Fiscal+2025+Financial+Results/24499253.html <p align="center"><em>The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals</em></p> <p align="center"><em>Post-merger </em><em>the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol</em><em>®</em><em> Cyclo™ </em></p> <p align="justify">NEWARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter and first six months of fiscal year 2025 ended January 31, 2025.</p> <p align="justify">“We look forward to the upcoming shareholder vote on our pending merger with Cyclo Therapeutics http://www.streetinsider.com/Press+Releases/Rafael+Holdings+Reports+Second+Quarter+Fiscal+2025+Financial+Results/24499253.html Thu, 13 Mar 2025 17:50:00 -0400 A.09213517 CYTH O.37720032 O.47731837 RFL http://www.streetinsider.com/Press+Releases/Rafael+Holdings+Reports+Second+Quarter+Fiscal+2025+Financial+Results/24499253.html <p align="center"><em>The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals</em></p> <p align="center"><em>Post-merger </em><em>the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol</em><em>®</em><em> Cyclo™ </em></p> <p align="justify">NEWARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter and first six months of fiscal year 2025 ended January 31, 2025.</p> <p align="justify">“We look forward to the upcoming shareholder vote on our pending merger with Cyclo Therapeutics http://www.streetinsider.com/Press+Releases/Rafael+Holdings+Reports+Second+Quarter+Fiscal+2025+Financial+Results/24499253.html Thu, 13 Mar 2025 17:50:00 -0400 A.09213517 CYTH O.37720032 O.47731837 RFL http://www.streetinsider.com/Press+Releases/Rafael+Holdings+Reports+Second+Quarter+Fiscal+2025+Financial+Results/24499253.html <p align="center"><em>The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals</em></p> <p align="center"><em>Post-merger </em><em>the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol</em><em>®</em><em> Cyclo™ </em></p> <p align="justify">NEWARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter and first six months of fiscal year 2025 ended January 31, 2025.</p> <p align="justify">“We look forward to the upcoming shareholder vote on our pending merger with Cyclo Therapeutics http://www.streetinsider.com/Press+Releases/Rafael+Holdings+Reports+Second+Quarter+Fiscal+2025+Financial+Results/24499253.html Thu, 13 Mar 2025 17:50:00 -0400 A.09213517 CYTH O.37720032 O.47731837 RFL http://www.streetinsider.com/Press+Releases/Rafael+Holdings+Reports+Second+Quarter+Fiscal+2025+Financial+Results/24499253.html <p align="center"><em>The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals</em></p> <p align="center"><em>Post-merger </em><em>the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol</em><em>®</em><em> Cyclo™ </em></p> <p align="justify">NEWARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter and first six months of fiscal year 2025 ended January 31, 2025.</p> <p align="justify">“We look forward to the upcoming shareholder vote on our pending merger with Cyclo Therapeutics http://www.streetinsider.com/Press+Releases/Rafael+Holdings+Reports+Second+Quarter+Fiscal+2025+Financial+Results/24499253.html Thu, 13 Mar 2025 17:50:00 -0400 A.09213517 CYTH O.37720032 O.47731837 RFL http://www.streetinsider.com/Press+Releases/Rafael+Holdings+Reports+Second+Quarter+Fiscal+2025+Financial+Results/24499253.html <p align="center"><em>The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals</em></p> <p align="center"><em>Post-merger </em><em>the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol</em><em>®</em><em> Cyclo™ </em></p> <p align="justify">NEWARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter and first six months of fiscal year 2025 ended January 31, 2025.</p> <p align="justify">“We look forward to the upcoming shareholder vote on our pending merger with Cyclo Therapeutics http://www.streetinsider.com/Press+Releases/Rafael+Holdings+Reports+Second+Quarter+Fiscal+2025+Financial+Results/24499253.html Thu, 13 Mar 2025 17:50:00 -0400 A.09213517 CYTH O.37720032 O.47731837 RFL http://www.streetinsider.com/Globe+Newswire/Rafael+Holdings+Reports+Second+Quarter+Fiscal+2025+Financial+Results/24499253.html <p align="center"><em>The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals</em></p> <p align="center"><em>Post-merger </em><em>the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol</em><em>®</em><em> Cyclo™ </em></p> <p align="justify">NEWARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter and first six months of fiscal year 2025 ended January 31, 2025.</p> <p align="justify">“We look forward to the upcoming shareholder vote on our pending merger with Cyclo Therapeutics http://www.streetinsider.com/Globe+Newswire/Rafael+Holdings+Reports+Second+Quarter+Fiscal+2025+Financial+Results/24499253.html Thu, 13 Mar 2025 17:50:00 -0400 A.09213517 CYTH O.37720032 O.47731837 RFL http://www.streetinsider.com/Globe+Newswire/Rafael+Holdings+Reports+Second+Quarter+Fiscal+2025+Financial+Results/24499253.html <p align="center"><em>The planned merger with Cyclo Therapeutics is anticipated to close in Q3 pending shareholder approvals</em></p> <p align="center"><em>Post-merger </em><em>the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol</em><em>®</em><em> Cyclo™ </em></p> <p align="justify">NEWARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter and first six months of fiscal year 2025 ended January 31, 2025.</p> <p align="justify">“We look forward to the upcoming shareholder vote on our pending merger with Cyclo Therapeutics http://www.streetinsider.com/Globe+Newswire/Rafael+Holdings+Reports+Second+Quarter+Fiscal+2025+Financial+Results/24499253.html Thu, 13 Mar 2025 17:50:00 -0400 A.09213517 CYTH O.37720032 O.47731837 RFL